Perspective Therapeutics, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in Perspective Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000703). The passive-investment giant's position makes it a notable institutional holder in the clinical-stage radiopharmaceutical company. The filing signals continued institutional interest in the small-cap biotech, which develops targeted alpha-particle therapies for cancer. Investors will watch for further 13G/13D amendments to see whether State Street's position grows or shrinks.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Perspective Therapeutics, Inc.